In early July 2018, the United States Food and Drug Administration (FDA) issued a final guidance document titled, “ANDA Submissions – Amendments to Abbreviated New Drug Applications under GDUFA – Guidance for Industry." A guidance document represents the current thinking and recommendations of the FDA, but is not legally binding.
Please see full publication below for more information.